These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7550855)

  • 1. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori.
    Hirai M; Azuma T; Ito S; Kato T; Kohli Y
    J Gastroenterol; 1995 Aug; 30(4):461-4. PubMed ID: 7550855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
    Sharara AI
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):863-70. PubMed ID: 16307499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro susceptibilities of Helicobacter pylori strains from children to proton pump inhibitors and its thioether derivative].
    Taneike I; Tamura Y; Shimizu T; Yamashiro Y; Toyoda S; Yamamoto T
    Kansenshogaku Zasshi; 2000 Jul; 74(7):601-2. PubMed ID: 10965666
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of lansoprazole in eradication of Helicobacter pylori.
    Takimoto T; Ido K; Taniguchi Y; Satoh K; Saifuku K; Kihira K; Yoshida Y; Kimura K
    J Clin Gastroenterol; 1995; 20 Suppl 2():S121-4. PubMed ID: 7594327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
    Miwa H; Ohkura R; Murai T; Sato K; Nagahara A; Hirai S; Watanabe S; Sato N
    Aliment Pharmacol Ther; 1999 Jun; 13(6):741-6. PubMed ID: 10383502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different biochemical modes of action of two irreversible H+,K(+)-ATPase inhibitors, omeprazole and E3810.
    Morii M; Takeguchi N
    J Biol Chem; 1993 Oct; 268(29):21553-9. PubMed ID: 8408006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
    Williams MP; Usselmann B; Chilton A; Sercombe J; Nwokolo CU; Pounder RE
    Aliment Pharmacol Ther; 2003 Mar; 17(6):775-83. PubMed ID: 12641499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori.
    Ohara T; Goshi S; Taneike I; Tamura Y; Zhang HM; Yamamoto T
    Helicobacter; 2001 Jun; 6(2):125-9. PubMed ID: 11422467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
    Suzuki M; Suzuki H; Kitahora T; Miyazawa M; Nagahashi S; Suzuki K; Ishii H
    Aliment Pharmacol Ther; 2002 Jan; 16(1):159-65. PubMed ID: 11856091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: the pharmacology of rabeprazole.
    Williams MP; Pounder RE
    Aliment Pharmacol Ther; 1999 Aug; 13 Suppl 3():3-10. PubMed ID: 10491723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor.
    Tsuchiya M; Imamura L; Park JB; Kobashi K
    Biol Pharm Bull; 1995 Aug; 18(8):1053-6. PubMed ID: 8535394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently.
    Tomiyama Y; Morii M; Takeguchi N
    Biochem Pharmacol; 1994 Nov; 48(11):2049-55. PubMed ID: 7802694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
    J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
    Giannini E; Romagnoli P; Fasoli A; Chiarbonello B; Malfatti F; Botta F; Risso D; Lantieri PB; Savarino V; Testa R
    Am J Gastroenterol; 2000 Oct; 95(10):2762-7. PubMed ID: 11051345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
    Kawabata H; Habu Y; Tomioka H; Kutsumi H; Kobayashi M; Oyasu K; Hayakumo T; Mizuno S; Kiyota K; Nakajima M; Kimoto K; Inokuchi H; Kawai K
    Aliment Pharmacol Ther; 2003 Jan; 17(2):259-64. PubMed ID: 12534411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
    Barth J; Hahne W
    Aliment Pharmacol Ther; 2002 Mar; 16 Suppl 1():31-3. PubMed ID: 11849125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori.
    Nakao M; Malfertheiner P
    Helicobacter; 1998 Mar; 3(1):21-7. PubMed ID: 9546114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
    Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M
    Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI; Goa KL
    Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
    Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
    Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.